Podchaser Logo
Home
Tricuspid Regurgitation: TEER for severe TR (Triluminate Pivotal Trial)

Tricuspid Regurgitation: TEER for severe TR (Triluminate Pivotal Trial)

Released Friday, 12th January 2024
Good episode? Give it some love!
Tricuspid Regurgitation: TEER for severe TR (Triluminate Pivotal Trial)

Tricuspid Regurgitation: TEER for severe TR (Triluminate Pivotal Trial)

Tricuspid Regurgitation: TEER for severe TR (Triluminate Pivotal Trial)

Tricuspid Regurgitation: TEER for severe TR (Triluminate Pivotal Trial)

Friday, 12th January 2024
Good episode? Give it some love!
Rate Episode

Key Points of the Study:

T-TEER with the TriClip device significantly improved health status in patients with severe tricuspid regurgitation (TR) compared to medical therapy alone.

This improvement was seen in both the short-term (1 month) and long-term (1 year) after the procedure.

T-TEER patients were more likely to be alive and well (defined as good KCCQ score and no decline) at 1 year compared to those on medical therapy.

The benefit of T-TEER was greater for patients with lower baseline health scores (KCCQ).

The health status improvement after T-TEER was likely due to reduced TR and correlated with reduced mortality and heart failure hospitalizations.

In conclusion, T-TEER is a promising treatment for severe TR, leading to significant and sustained improvement in health status and quality of life for patients.


Link to article:

https://doi.org/10.1016/j.jacc.2023.10.008

---

Send in a voice message: https://podcasters.spotify.com/pod/show/dr-bishnu-subedi/message

Show More

Unlock more with Podchaser Pro

  • Audience Insights
  • Contact Information
  • Demographics
  • Charts
  • Sponsor History
  • and More!
Pro Features